It’s only fair to share… Cenacitinib CAS 2641636-52-2 MF C19H19F2N7O3 MW431.4 Urea, N-[(1R,2S)-2-fluorocyclopropyl]-N′-[5-[(7-fluoro-2,3-dihydro-1,4-benzodioxin-5-yl)amino]-7-(methylamino)pyrazolo[1,5-a]pyrimidin-3-yl]- N-{5-[(7-fluoro-2,3-dihydro-1,4-benzodioxin-5-yl)amino]-7-(methylamino)pyrazolo[1,5-a]pyrimidin-3-yl}-N′-[(1R,2S)-2-fluorocyclopropyl]urea Janus kinase inhibitor, anti-inflammatory, VTX958, VTX 958, SB88R8KGL3 VTX958 for the Treatment of Moderately to Severely Active Crohn’s Disease CTID: NCT05688852 Phase: Phase 2 Status: Terminated Date: 2025-07-03 SYN [US20210139486] https://patentscope.wipo.int/search/en/detail.jsf?docId=US323750705&_cid=P22-MKEUDK-45432-1 Example 4: Synthesis of 1-(5-((7-fluoro-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)amino)-7-(methylamino)pyrazolo[1,5-a]pyrimidin-3-yl)-3-((1R,2S)-2-fluorocyclopropyl)urea (5) Step 1: To a solution of 1E (100 …